Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations
NCT06965790 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2025-12-09
Summary
A large proportion of radiological CT examinations require the intravenous administration of iodine-containing X-ray contrast medium. According to current guidelines, the amount required for CT examinations in the (portal) venous phase is calculated on the basis of body weight (e.g. 0.2-0.4 g iodine/kg body weight), but a standardized application dose of the contrast agent is often also used.
In earlier studies, the investigators found that the iodine contrast in vessels and organs achieved with a standardized amount of contrast agent differs significantly between women and men. On average, women showed around 10% higher iodine contrast than men of the same height and weight. The investigators attribute these differences to physiological, sex-specific differences in blood volume. For example, the blood volume of a woman 175 cm tall and weighing 75 kg is approx. 400 ml less than that of a man of the same height and weight (approx. 4.6 vs. 5.0 l, calculated according to Nadler). Taking blood volume into account, sex was no longer a significant influencing factor in a retrospective cohort (n=274).
The investigators would now like to investigate these results in a prospective study. For this purpose, two groups of patients with a clinical indication for a contrast-enhanced CT scan in the venous phase will be compared:
1. control group with regular weight-adjusted (n = 200)
2. study group with dosing according to blood volume (n = 200).
The hypothesis is that the application scheme adapted to the blood volume leads to a more homogeneous contrasting of women and men. In order to quantify this effect, the iodine contrast values of both groups will be quantitatively analyzed, taking into account other influencing variables (height, weight).
The investigators hope that this approach will reduce or even eliminate the observed sex-specific differences. This would lead to a sex-equal contrast based on an individualized amount of contrast medium.
Conditions
- CT Scans
- Contrast Media
- Gender
- Womens Health
Interventions
- DRUG
-
contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume
Calculation of the standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg) and calculation of the specific blood volume using the established Nadler formula for male and female. Adjustment of the contrast agent according to the ratio of the blood volumes. The amount of saved contrast agent is replaced 1:1 by NaCl.
Sponsors & Collaborators
-
University Hospital Augsburg
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-01
- Primary Completion
- 2026-03-31
- Completion
- 2027-03-31
Countries
- Germany
Study Locations
More Related Trials
-
Comparison of Contrast Agent Administration Protocols
NCT04300972 ·Status: COMPLETED ·Phase: NA
-
Comparison of Contrast Agents During CT Angiography
NCT01534975 ·Status: COMPLETED ·Phase: NA
-
Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
NCT02669784 ·Status: COMPLETED ·Phase: NA
-
A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting
NCT02840903 ·Status: COMPLETED
-
Customized Contrast Media Dose Clinical Trial
NCT02433665 ·Status: TERMINATED ·Phase: NA
-
Chest CT Using Low-concentration Iodine Contrast Media
NCT05967117 ·Status: RECRUITING ·Phase: PHASE4
-
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
NCT00244140 ·Status: COMPLETED ·Phase: PHASE3
-
Optimization of Contrast Agent Dose in CT With Lean Body Weight
NCT03384979 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease
NCT00165620 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose Contrast Media for Low-kVp Abdomen CT
NCT05878665 ·Status: RECRUITING ·Phase: NA
-
Relationship Between Contrast Media Volume and Tube Voltage in CT for Optimal Liver Enhancement, Based on Body Weight.
NCT03735706 ·Status: COMPLETED ·Phase: NA
-
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
NCT00478556 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination
NCT05537779 ·Status: UNKNOWN
-
The Best Parameters for Imaging Agent Injection and Scanning Methods in Computed Tomography Angiography
NCT04832633 ·Status: COMPLETED ·Phase: NA
-
Dual Energy CT Urography With Reduced Iodinated Contrast
NCT02283307 ·Status: COMPLETED ·Phase: NA
-
CT DOSE Collaboratory
NCT03000751 ·Status: COMPLETED ·Phase: NA
-
Emergency Department CT Scanning for Appendicitis
NCT00734825 ·Status: COMPLETED ·Phase: NA
-
Abdominal Computed Tomography and the Blood Reactive Oxygen Species Level
NCT00745641 ·Status: WITHDRAWN
-
Contrast Media Temperature and Patient Comfort in CT of the Abdomen
NCT04249479 ·Status: COMPLETED ·Phase: NA
-
Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA
NCT05489055 ·Status: UNKNOWN ·Phase: NA
-
Imaging Techniques in CT: Technical Development
NCT02242448 ·Status: TERMINATED
-
Risk Factors and Computed Tomography Findings in COVID-19.
NCT04577105 ·Status: COMPLETED
-
Multidetector Computed Tomography (MDCT) Tailored Protocol
NCT01737333 ·Status: COMPLETED
-
The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia
NCT06445660 ·Status: RECRUITING
-
Uniformity of Oral Contrast Material in the Bowel
NCT02542046 ·Status: COMPLETED